PE Investors Sign LOI for Sinuwave Technologies

Ondine Biopharma (TSX: OBP) has agreed to sell a majority position in a to-be-formed subsidiary, Sinuwave Technologies, to a group of undisclosed European private equity investors. Sinuwave will develop photodisinfection solutions for the chronic sinusitis market. The total deal could be valued at around $3.1 million.

DealsNorth AmericaUSBriefs